New antipsychotic medications: More than old wine and new bottles

S. Charles Schulz

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Four new antipsychotic medications - clozapine, risperidone, olanzapine, and quetiapine - have been introduced in the United States during the past decade. These new medications now account for the majority of antipsychotic prescriptions. The author reviews specific issues related to the use of traditional antipsychotic medications and then highlights the emerging clinical research data regarding the new medications, which have all been shown to be efficacious in the treatment of schizophrenia. Clinical research data indicate that they are also more useful for a broader array of symptoms associated with schizophrenia than traditional compounds. Furthermore, movement disorder side effects are substantially decreased - a property that leads to higher acceptability. Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings. These dosing issues are described. New uses, including treatment of mood disorders and conduct disorder, are also discussed. These medicines offer substantial hope for improved treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)60-75
Number of pages16
JournalBulletin of the Menninger Clinic
Issue number1
StatePublished - Dec 2000


Dive into the research topics of 'New antipsychotic medications: More than old wine and new bottles'. Together they form a unique fingerprint.

Cite this